Etoposide in Treating Young Patients With Relapsed Ependymoma


RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.

Full Title of Study: “Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2010

Detailed Description

OBJECTIVES: Primary – Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide. Secondary – Determine the possibility of second surgery or additional radiotherapy in these patients. OUTLINE: This is a multicenter study. Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical resection. After completion of study treatment, patients are followed periodically for approximately 5 years. PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.


  • Drug: etoposide
  • Procedure: conventional surgery

Clinical Trial Outcome Measures

Primary Measures

  • Response rate by MRI after course 3

Secondary Measures

  • Second surgery or additional radiotherapy in responding patients as assessed by MRI scan after course 3 or 6

Participating in This Clinical Trial


  • Histologically confirmed intracranial ependymoma at first, second, or third relapse – Anaplastic (malignant) or low-grade ependymoma (cellular, papillary, clear cell, or mixed variants) – Unequivocal evidence of tumor recurrence or progression by MRI scan after failing conventional treatment (e.g., primary surgery and adjuvant radiotherapy) for initial or recurrent disease – Unresectable disease OR not amenable to complete surgical resection – Measurable enhancing or non-enhancing disease on baseline scan performed within the past 2 weeks – Patients who have undergone prior surgery must have residual measurable disease PATIENT CHARACTERISTICS: – Lansky performance status 30-100% – Life expectancy ≥ 8 weeks – Absolute neutrophil count > 1,000/mm^3 – Platelet count > 100,000/mm^3 – Serum total bilirubin normal – AST < 2 times upper limit of normal – No unrelated medical condition (e.g., renal or liver impairment) that would preclude chemotherapy treatment – No active infection – No known HIV positivity PRIOR CONCURRENT THERAPY: – See Disease Characteristics – No radiotherapy within the past 6 weeks – No chemotherapy within the past 4 weeks – Prior IV etoposide allowed

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Cancer and Leukaemia Group
  • Overall Official(s)
    • Linda S. Lashford, , The Christie NHS Foundation Trust
    • Susan V. Picton, MD, Study Chair, Leeds Cancer Centre at St. James’s University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.